Public comments to FDA following the agency’s March 27 meeting on the scope of DSHEA show broad industry consensus that the current FDA reading of “dietary substance” is too narrow and out of step with modern science. Trade associations and independent experts urged the agency to recognize ingredients produced through fermentation, cell culture, and other novel methods as eligible, while keeping safety enforcement rigorous through DSHEA’s existing tools. The outcome of FDA’s review could fundamentally reset what counts as a lawful supplement ingredient.

Following an April 29 Energy and Commerce Subcommittee on Health hearing, Rep. Nick Langworthy reaffirmed support for H.R. 7366, his Dietary Supplement Regulatory Uniformity Act. The bill, introduced in February, would establish federal preemption over conflicting state supplement laws while preserving DSHEA’s national framework. Industry trade groups view the legislation as a key bulwark against a rising tide of state-level age restrictions and ingredient bans.

A new Bloomberg feature paints FDA Commissioner Marty Makary as increasingly isolated, citing staff clashes, leadership turnover, and industry backlash one year into his tenure at an agency now overseeing major DSHEA-era policy shifts. The reporting raises questions about continuity for FDA initiatives that directly impact supplements, including the disclaimer label review and the dietary substance scope rulemaking. Industry watchers will be tracking whether leadership turbulence slows or accelerates Makary’s MAHA-aligned agenda.

A STAT First Opinion piece warns that Health Secretary Robert F. Kennedy Jr.’s effort to move several peptides off FDA’s restricted compounding list could open consumers to unproven and potentially unsafe products. The debate intersects directly with the supplement industry, where some manufacturers have begun blending peptides into capsules, gummies, and powders. The piece highlights the regulatory tension between MAHA-driven access expansion and DSHEA’s existing safety guardrails.

After White House pressure to pull back from vaccine policy fights, Secretary Kennedy is pivoting toward fast wins that include peptide reclassification and dietary supplement reform ahead of November’s midterm elections. The strategy makes supplements a high-visibility political target, increasing both opportunity and scrutiny for the industry. DSHEA stakeholders will need to balance engagement with the MAHA agenda against the risk of overreach that could invite regulatory backlash.

Consumer groups including EWG, US Right to Know, and Children’s Health Defense are pressing Congress to reject the FRESH Act, which contains preemption language affecting dietary supplements. Critics argue the bill would erase recent state-level protections, including restrictions on supplement sales to minors and heavy metal testing rules. The fight underscores the central preemption debate now running through nearly every major supplement bill in the 119th Congress.

Health Canada’s Natural and Non-prescription Health Products Directorate released a new prebiotics monograph establishing a Canadian regulatory framework for prebiotic ingredients and claims. Industry groups including the International Probiotics Association and Global Prebiotics Association contributed input, signaling growing global alignment on gut health categories. U.S. supplement makers exporting north of the border should expect clearer pathways but tighter substantiation expectations.

A nutraceutical consultant has launched SuppleMate by Remedy, a consumer-facing app that scores supplements on scientific credibility, regulatory status, dose efficacy, and ingredient interactions. The tool reflects a market that increasingly rewards substantiated science and clean formulations as MAHA scrutiny grows. For DSHEA-aligned brands, transparency tools may become a meaningful competitive moat.

Vitafoods Europe, kicking off May 5 in Barcelona, is set to spotlight gut health, healthspan and longevity, GLP-1 companion products, and cognitive health, mirroring U.S. category trends. The event’s regulatory programming will track how Europe’s supplement frameworks compare against the evolving DSHEA modernization agenda in Washington. North American brands continue to use Vitafoods as a key barometer for global ingredient direction.

NutraIngredients’ April product roundup highlights personalized wellness platforms, ingestible beauty formats, and continued gut health innovation, with brands leaning into clinically backed ingredients to capture MAHA-era consumers. Several launches reflect the broader pivot toward science-led claims that would align with the FDA’s evolving disclaimer and ingredient policies. The mix points to a category where DSHEA’s structure-function framework remains a powerful innovation enabler.